Glenmark Pharmaceuticals’ arm enters into an agreement with Forest Laboratories, Inc

24 Dec 2012 Evaluate

Glenmark Pharmaceuticals (GPL), a leading Indian multinational pharmaceutical company’s - wholly owned subsidiary - Glenmark Pharmaceuticals S.A (GPSA), has entered into an agreement with Forest Laboratories, Inc., an international health care leader, on collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Glenmark has identified clinical candidates and is currently conducting pre-clinical studies and other development activities required to support the initiation of first-in-human dosing.

Under the terms of the agreement, Forest will make a $6 million upfront payment to Glenmark and provide an additional $3 million to support the next phase of work. Forest will make other future payments in FY2014 to support the advancement of the ongoing mPGES-1 inhibitors program. Forest has an exclusive option to obtain license rights to the program upon the completion of Phase 1 clinical trials.

Both parties will work collaboratively to advance the program into the clinic. The collaboration between Glenmark and Forest will be managed by a Joint Development Committee with equal representation from both companies.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×